Related Experiment Videos
Indisulam. Eisai
1Universita degli Studi di Firenze, Dipartimento di Chimica, Via della Lastruccia, 3, Rm 188, I-50019 Sesto Fiorentino, Italy. claudiu.supuran@unifi.it
Idrugs : the Investigational Drugs Journal
|June 12, 2003
Summary
Indisulam, a novel sulfonamide, is being developed to treat cancer by halting cell cycle progression. Clinical trials are underway in Europe and the US, with development planned for Japan.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Indisulam is a sulfonamide derivative developed by Eisai and the EORTC.
- It functions by inhibiting cell cycle progression at the G(1) phase.
- This mechanism suggests potential as an anti-cancer therapeutic.
Purpose of the Study:
- To evaluate the efficacy and safety of indisulam in cancer patients.
- To determine the optimal dosage and treatment regimen for indisulam.
- To advance the clinical development of indisulam for solid tumors.
Main Methods:
- Phase II clinical trials in Europe and the United States.
- Ongoing patient enrollment and data collection.
- Monitoring of treatment response and adverse events.
Main Results:
- Indisulam demonstrated inhibition of cell cycle progression.
- Phase II trials for solid tumors were initiated in Europe (January 2001) and the US (March 2001).
- Clinical development in Japan was scheduled for fiscal year 2002.
Conclusions:
- Indisulam shows promise as a novel anti-cancer agent.
- Further clinical investigation is warranted to establish its therapeutic role.
- The drug's development is progressing across multiple international regions.